(Sharecast News) - Liquid biopsy company Angle received "breakthrough results" from DNA molecular analysis of cancer patient blood samples on Thursday, sending its shares skywards as a result.
Angle said its technology had successfully identified "key DNA mutations" in circulating tumour cells (CTCs) that had not been detected in ctDNA during a recent study involving 47 patients with breast, lung, prostate, and ovarian cancers.
The AIM-listed group highlighted that the study had revealed that in 70% of breast and lung cancer samples, and 60% of ovarian cancer samples, actionable DNA variants were found in CTCs but not in ctDNA, highlighting the potential for its technology to provide more comprehensive insights into cancer progression and treatment options.
Chief scientific officer Dr Karen Miller said: "This new clinical evidence highlights the strength of the Parsortix system to provide the best possible sample for analysis, enabling DNA profiling of both the living CTCs and ctDNA released from dead cells from the patient's cancer.
"We are particularly excited about finding such high levels of additional variants in the CTCs that are not present in ctDNA, as this provides potentially additional information for the clinicians on which to base their treatment options."
As of 0915 GMT, Angle shares had surged 43.4% to 19.0p.
Reporting by Iain Gilbert at Sharecast.com
Angle (AGL)